# Progress and challenges in transplantation of human pluripotent stem cell derived cardiomyocytes for cardiac therapy

## TL;DR

This paper reviews progress and challenges in using stem cell-derived heart cells for treating heart disease.

## Contribution

The paper provides a comprehensive overview of recent advancements and challenges in translating hPSC-CMs into clinical therapies.

## Key findings

- Advancements in hPSC-CM differentiation and manufacturing have improved scalability and clinical readiness.
- Preclinical and clinical studies show potential for hPSC-CMs to repair damaged heart tissue.
- Key challenges include optimizing delivery methods and understanding repair mechanisms.

## Abstract

Myocardial infarction and heart failure remain leading causes of mortality worldwide. Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) represent a promising approach to regenerating damaged myocardium and restoring cardiac function. This review highlights advancements in hPSC-CM differentiation, scale-up, and clinical-grade manufacturing; delivery approaches; and insights from preclinical and clinical studies. We also examine mechanisms of repair, key challenges and mitigation strategies, and future directions to advance hPSC-CM therapies toward clinical translation.